Michael S. Richman

Founder at NextCure, Inc.

Michael S. Richman

Michael S. Richman

Founder at NextCure, Inc.

Overview
Career Highlights

MacroGenics, Inc.
Amplimmune, Inc.
NextCure, Inc.

RelSci Relationships

2405

Number of Boards

12

Birthday

1960

Age

59

Contact Data
Trying to get in touch with Michael S. Richman? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Michael S. Richman likely has professional access to. A relationship does not necessarily indicate a personal connection.

Partner at OrbiMed Advisors LLC

Relationship likelihood: Strong

Professor at Johns Hopkins University

Relationship likelihood: Strong

Executive Partner, Private Equity at Sofinnova Ventures, Inc.

Relationship likelihood: Strong

Venture Partner at Canaan Management, Inc.

Relationship likelihood: Strong

Partner at Lilly Asian Ventures

Relationship likelihood: Strong

Director at Codeco Corp.

Relationship likelihood: Strong

Executive Director at Albert & Margaret Alkek Foundation

Relationship likelihood: Strong

Chief Executive Officer, President & Director at Pieris Pharmaceuticals, Inc.

Relationship likelihood: Strong

Independence Chairman of the Board at Genvec Inc.

Relationship likelihood: Strong

Former Finance Director at Ciba Geigy Corp.

Relationship likelihood: Strong

Paths to Michael S. Richman
Potential Connections via
Relationship Science
You
Michael S. Richman
Founder at NextCure, Inc.
Education
M.S.B.A. International Business

San Francisco State University was established in 1899 as a teacher-training school. SF State has been known for its commitment to excellent teaching. Students work closely with senior professors and other instructors from freshman year through graduation. Trained in some of the finest institutions in the world, faculty members include winners of prestigious teaching awards, cutting-edge researchers, and professionals devoted to solving community problems.

B.S. Genetics & Molecular Biology

The University of California, Davis (also referred to as UCD, UC Davis, or Davis) is a public teaching and research university located in Davis, California just west of Sacramento. The campus covers 7,309 acres (2,958 ha), making it the largest within the 10 campus University of California system. UC Davis also has the third largest enrollment in the UC System after UCLA and UC Berkeley. The University of California, Davis campus is the largest campus in the UC system by land area, spanning 7,309 acres (2,957.8 ha) across two counties: Yolo and Solano. Though named after the City of Davis, the campus is technically located adjacent to the City of Davis in an unincorporated part of Yolo and Solano counties. The main campus is located 15 miles (24.1 km) west of Sacramento in the Sacramento Valley, part of California's Central Valley, and is adjacent to Interstate Highway 80. The Davis campus is the only school within the UC system with an airport, just west of main campus, and is one of two UC schools with its own fire department; the other being UC Santa Cruz. The campus is also conveniently located approximately an hour away from both San Francisco and the Napa Valley and two hours from Lake Tahoe. It is also one of only three schools in the University of California system, the others being UC Berkeley and UC Irvine, with a nuclear lab.

Career History
President & Chief Executive Officer
2007 - 2015

Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD.

Senior Vice President-Corporate Development & Administration
1996 - 2002

MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD.

Director-Corporate Business Development
1988 - 1992

Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA.

Boards & Committees
President, Chief Executive Officer & Director
2015 - Current

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lieping Chen in September 2015 and is headquartered in Beltsville, MD.

Director
2014 - Current

Madison Vaccines, Inc. develops vaccines for patients with prostate cancer. It is also developing a sensitivity test to identify those patients who will derive clinical benefit from these vaccines. The firm develops immunological therapies in patients with minimal residual disease, and for whom the mechanism of action of vaccines is ideally suited. The company was founded by Richard R. Lesniewski and Douglas G. McNeel in 2012 and is headquartered in Madison, WI.

Independent Director
2014 - Current

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Transactions
Details Hidden

NextCure, Inc. raised money in a private placement transaction

Details Hidden

NextCure, Inc. raised money in a private placement transaction

Details Hidden

MedImmune LLC, AstraZeneca Plc purchase Amplimmune, Inc. from InterWest Partners, LLC

Investments
Details Hidden

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lieping Chen in September 2015 and is headquartered in Beltsville, MD.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Michael S. Richman. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Michael S. Richman's profile does not indicate a business or promotional relationship of any kind between RelSci and Michael S. Richman.